.

Dr Laila Samady-Mustad, PhD, joins the investment team at RYSE Asset Management

We’re thrilled to announce that Dr Laila Samady-Mustad, PhD has joined us in our mission to build a global digital future for healthcare!

Laila is a successful entrepreneur, research scientist, and business strategist with 20 years’ experience in the pharmaceutical, medical, and biotechnology industry in the UK, US, and France.

Her expertise is in medical affairs, partnership, business development, and capital raising strategies. She is Chair of the Board of Advisors and Chief Scientific Officer at Vigilent Labs (digital health), Vice President at Covanos (med tech), Vice President at G3 Therapeutics (biotech), and while at Boehringer Ingelheim, she served in increasingly senior positions culminating with a global partnership role.

Laila holds a PhD from University College London (UCL) and her work led to a spin out company, BioVex, which was acquired by Amgen for $1Bn!

You can read the article on our LinkedIn page here.